ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,815.03
0.61%
US Tech 100
19,700.00
-0.02%
Dow Jones
42,863.86
0.97%
Brent Oil
78.695
0.00%
Bitcoin
62,732.56
0.45%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Merus NV (MRUS) Quote

Merus NV

Merus NV (MRUS)

NASDAQ
53.40
0.78
(1.48%)
Closed October 12 4:00PM
Delayed by 15 minutes
53.39
-0.01
(-0.02%)
After Hours: 7:59PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
53.40
Bid
50.91
Ask
55.42
Volume
363,827
52.41 Day's Range 53.76
19.805 52 Week Range 61.61
Market Cap
3.642B
Previous Close
52.62
Open
52.73
Last Trade
10
@
53.4
Last Trade Time
Financial Volume
$ 19,370,906
VWAP
53.2421
Average Volume (3m)
512,909
Shares Outstanding
68,210,479
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
43.95M
Net Profit
-154.94M

About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector
Gen Med & Surgical Hospitals
Industry
Gen Med & Surgical Hospitals
Website
www.merus.nl
Headquarters
Utrecht, Utrecht, Nld
Founded
-
Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $52.62. Over the last year, Merus NV shares have traded in a share price range of $ 19.805 to $ 61.61.

Merus NV currently has 68,210,479 shares outstanding. The market capitalization of Merus NV is $3.59 billion.

Ask ADVFN Intelligence (AI)

MRUS Latest News

More News

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

September 30 2024
GlobeNewswire Inc.

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

September 17 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

August 22 2024
Edgar (US Regulatory)

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

August 06 2024
GlobeNewswire Inc.

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial...

August 01 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 01 2024
Edgar (US Regulatory)

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

July 24 2024
GlobeNewswire Inc.

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

July 08 2024
GlobeNewswire Inc.

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

July 01 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

June 17 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.025.9944422389850.3853.3949.8569795252.16704106CS
44.038.1628519343749.3753.3946.6560815950.17488948CS
12-1.9-3.4358047016355.356.6246.6551290951.13835022CS
2611.1526.390532544442.2561.6139.2778696851.95143645CS
5232.16151.41242937921.2461.6119.80564944045.30310697CS
15625.12588.859416445628.27561.6112.0341546034.22647613CS
26036.79221.4930764616.6161.6110.1831782631.18825114CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
$ 7.14
(233.64%)
154.23M
NIVFNewGenIvf Group Ltd
$ 0.98
(63.42%)
58.51M
ATIFATIF Holdings Ltd
$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
$ 0.299
(-35.28%)
11.11M
TURBTurbo Energy SA
$ 2.1511
(-29.01%)
3.2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
$ 7.898
(-23.62%)
993.33k
VEEAVeea Inc
$ 3.27
(-23.24%)
284.95k
INHDInno Holdings Inc
$ 3.74
(-22.41%)
257.75k
JTAIJet AI Inc
$ 0.1009
(23.50%)
340.09M
CDTConduit Pharmaceuticals Inc
$ 0.116
(13.28%)
270.97M
NVDANVIDIA Corporation
$ 134.80
(-0.01%)
170.27M
LUXHLuxUrban Hotels Inc
$ 0.0532
(5.35%)
165.94M
TWGTop Wealth Group Holding Ltd
$ 7.14
(233.64%)
154.23M

MRUS Discussion

View Posts
Monksdream Monksdream 4 weeks ago
MRUS range bound
👍️0
Phosphene Phosphene 4 years ago
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
👍️0
Phosphene Phosphene 4 years ago
The Baker Brothers have 7% ownership.

https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
👍️0
Phosphene Phosphene 4 years ago
Board Member: Victor Sandor

https://ir.merus.nl/board-member/victor-sandor

https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
👍️0
Phosphene Phosphene 4 years ago
Second Quarter 2020 Results:

https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
👍️0
Phosphene Phosphene 4 years ago
https://merus.nl/
👍️0
Phosphene Phosphene 4 years ago
European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
👍️0

Your Recent History

NASDAQ
MRUS
Merus NV
NYSE
IP
International Paper
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved